October 2018 – The CenterWatch Monthly : pdf
Will Master Protocols Become the Norm?
As an increasing number of sponsors turn to master protocols as a way to reach decision points more quickly, the FDA says it’s ready to give new clinical trial designs a shot if they promise to help speed safe and effective drugs to market.
Rise of the Machines: AI Creeps into Clinical Trials
Artificial intelligence not only promises to increase the speed and accuracy of clinical trial recruitment and analysis but also to drastically reduce drug development costs.
Also in this issue:
- Regulatory Update
- FDA Actions